Drs. Ben-David and Joyce evaluate the performance of ctDNA in detecting localized RCC disease recurrence after surgery.
Renal Cell Carcinoma
Advertisement
Latest News
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Dr. Samuel Gold shares some perspective on the impact of disease recurrence on HRQoL after radical cystectomy.
Advertisement
Advertisement
Latest News
Drs. Ben-David, Joyce share an analysis on recurrence-free survival according to ctDNA status in patients with renal masses.
Dr. Ghoreifi explains how results suggest feasibility with high rates of pathological downstaging and complete response.
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.